Researchers at the University of Zurich have determined the three-dimensional structure of a receptor that controls the release of calcium from bones. The receptor is now one of the main candidates for developing new drugs to treat osteoporosis. Knowing the receptor’s blueprint will be instrumental for designing drugs that could even help to rebuild bones.
Osteoporosis affects about 400,000 people in Switzerland, mostly women after menopause. It is often described as a silent disease, because bone loss usually occurs little by little over the years and without any symptoms.
The body gradually absorbs calcium from the bones, which become brittle. This process is controlled via what is called the parathyroid hormone (PTH) and a closely related peptide – a protein fragment.
They bind to the PTH-1 receptor, thereby telling the body to either release calcium from the bone or to build new bone.
An extremely difficult undertaking
A team led by Andreas Plückthun, professor at the Department of Biochemistry of the University of Zurich (UZH), has now been able to determine the three-dimensional structure of the PTH-1 receptor.
The atomic structure can now serve as the blueprint for the future development of drugs. Such receptor-binding compounds may slow down, and perhaps even reverse, osteoporosis to some degree.
Determining the structure of this receptor was an extremely tough undertaking, as cells only produce a very small amount of it, and it is also very unstable.
“The directed evolution and protein engineering methods we have developed over the last few years were absolutely instrumental in making this possible,” explains Andreas Plückthun.
Disadvantages of current treatment
One of the most effective current treatments for severe osteoporosis involves the use of substances that look like the natural hormone and its related peptide.
“However, this treatment is extremely expensive. The substances have to be injected into the thigh or abdomen once a day, and the treatment also has significant side effects,” says Christoph Klenk, co-author of the study.
The scientists are convinced that thanks to the new insights into the mechanisms of the PTH-1 receptor, new drugs can be developed that don’t have any of the previous disadvantages.
“The receptor is like a lock, and the peptides are the keys that turn it,” describes Plückthun. “Having the atomic 3D blueprint on a computer screen gives us an unprecedented level of insight into how the lock actually works.”
Understanding a whole class of receptors
The PTH-1 receptor is a member of the family of G protein-coupled receptors. In particular, these include receptors that bind to other hormones, such as the ones involved in controlling diabetes.
The work by the UZH scientists thus also sheds light on how the whole family of receptors works, as the PTH-1 receptor was examined at the highest level of detail for any of these receptors so far.
This has enabled the scientists to describe similarities as well as differences to other class B receptors. “Having the blueprint of the lock doesn’t give us a key yet, but now it’s possible to build one,” says Andreas Plückthun.
Prof. Andreas Plückthun, PhD
Department of Biochemistry
University of Zurich
Phone: +41 44 635 55 70
Janosch Ehrenmann, Jendrik Schöppe, Christoph Klenk, Mathieu Rappas, Lutz Kummer, Andrew S. Doré, Andreas Plückthun. High-resolution crystal structure of parathyroid hormone 1 receptor in complex with a peptide agonist. Nature Structural and Molecular Biology, November 19, 2018. DOI: 10.1038/s41594-018-0151-4
Kurt Bodenmüller | Universität Zürich
Mass spectrometry sheds new light on thallium poisoning cold case
14.12.2018 | University of Maryland
Protein involved in nematode stress response identified
14.12.2018 | University of Illinois College of Agricultural, Consumer and Environmental Sciences
The more objects we make "smart," from watches to entire buildings, the greater the need for these devices to store and retrieve massive amounts of data quickly without consuming too much power.
Millions of new memory cells could be part of a computer chip and provide that speed and energy savings, thanks to the discovery of a previously unobserved...
What if, instead of turning up the thermostat, you could warm up with high-tech, flexible patches sewn into your clothes - while significantly reducing your...
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth – this was discovered by researchers from the University of Basel’s Biozentrum two years ago. In a follow-up study, recently published in “Cell Reports”, the scientists report that this drug cocktail induces cancer cell death by switching off their energy supply.
The widely used anti-diabetes drug metformin not only reduces blood sugar but also has an anti-cancer effect. However, the metformin dose commonly used in the...
A research team from the University of Zurich has developed a new drone that can retract its propeller arms in flight and make itself small to fit through narrow gaps and holes. This is particularly useful when searching for victims of natural disasters.
Inspecting a damaged building after an earthquake or during a fire is exactly the kind of job that human rescuers would like drones to do for them. A flying...
Over the last decade, there has been much excitement about the discovery, recognised by the Nobel Prize in Physics only two years ago, that there are two types...
12.12.2018 | Event News
10.12.2018 | Event News
06.12.2018 | Event News
14.12.2018 | Power and Electrical Engineering
14.12.2018 | Physics and Astronomy
14.12.2018 | Physics and Astronomy